IRIS
CORTELLINI, ALESSIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.510
EU - Europa 709
AS - Asia 132
Continente sconosciuto - Info sul continente non disponibili 3
OC - Oceania 3
Totale 2.357
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.509
IE - Irlanda 413
UA - Ucraina 85
CN - Cina 82
DE - Germania 64
IT - Italia 50
SE - Svezia 37
VN - Vietnam 19
TR - Turchia 15
BE - Belgio 13
GB - Regno Unito 13
FI - Finlandia 7
IN - India 6
FR - Francia 5
RU - Federazione Russa 5
EU - Europa 3
JP - Giappone 3
PT - Portogallo 3
BG - Bulgaria 2
CH - Svizzera 2
ID - Indonesia 2
NZ - Nuova Zelanda 2
RS - Serbia 2
AT - Austria 1
AU - Australia 1
CA - Canada 1
CY - Cipro 1
ES - Italia 1
IL - Israele 1
KR - Corea 1
LU - Lussemburgo 1
MC - Monaco 1
MD - Moldavia 1
MK - Macedonia 1
NL - Olanda 1
PH - Filippine 1
RO - Romania 1
SG - Singapore 1
Totale 2.357
Salva come PNG Salva come JPEG
Città #
Chandler 430
Dublin 413
Jacksonville 305
Ashburn 103
New York 65
Ann Arbor 61
Princeton 58
Lawrence 57
Wilmington 42
Beijing 37
Boardman 28
Bremen 21
Dong Ket 18
Dearborn 17
Brussels 13
L'aquila 13
Izmir 10
Nanjing 9
Milan 7
Helsinki 6
Nanchang 6
Norwalk 5
Pune 5
San Mateo 5
Cagliari 4
Jinan 4
Redwood City 4
San Francisco 4
Seattle 4
Tianjin 4
Woodbridge 4
Des Moines 3
Guangzhou 3
Jiaxing 3
Stockholm 3
Tokyo 3
Edinburgh 2
Frankfurt am Main 2
Hefei 2
Kunming 2
Ningbo 2
Redmond 2
Shenyang 2
Sofia 2
Vittuone 2
Zhengzhou 2
Zurich 2
Amsterdam 1
Aquila 1
Atlanta 1
Belgrade 1
Canberra 1
Changchun 1
Chisinau 1
Città Sant'Angelo 1
Haikou 1
Hamburg 1
Hanoi 1
Houston 1
Istanbul 1
Jakarta 1
Lanciano 1
Lisbon 1
Los Angeles 1
Luxembourg 1
Manchester 1
Manila 1
Monaco 1
Nelson 1
New Orleans 1
Nicosia 1
Nizhniy Novgorod 1
Phoenix 1
Quzhou 1
Seoul 1
Shanghai 1
Singapore 1
Skopje 1
Surabaya 1
Taizhou 1
Tel Aviv 1
Torre Del Greco 1
Vancouver 1
Vienna 1
Washington 1
Wellington 1
Totale 1.838
Salva come PNG Salva come JPEG
Nome #
KRAS and Two Rare PI3KCA Mutations Coexisting in a Metastatic Colorectal Cancer Patient With Aggressive and Resistant Disease. 91
"Vessels in the Storm": Searching for Prognostic and Predictive Angiogenic Factors in Colorectal Cancer 84
two simulteneous and very uncommom pi3kca mutations in a liver metastasis from colorectal cancer patient with aggressive and resistant disease 73
Multicentric retrospective analysis of platinum-pemetrexed regimens as first-line therapy in non-squamous non-small cell lung cancer patients: A "snapshot" from clinical practice 68
Early fatigue in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: An insight from clinical practice 60
Evaluating the role of FAMIly history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 study 59
Palliative radiotherapy in advanced cancer patients treated with immune‑checkpoint inhibitors: The PRACTICE study 54
Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients 53
Intra-patient Heterogeneity of BRAF and NRAS Molecular Alterations in Primary Melanoma and Metastases 52
Safe Administration of Ipilimumab, Pembrolizumab, and Nivolumab in a Patient with Metastatic Melanoma, Psoriasis, and a Previous Guillain-Barré Syndrome 51
A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: When overweight becomes favorable 50
The PERSONS score: A new tool for cancer patients' symptom assessment in simultaneous care and home care settings 50
Expression of pro-angiogenic factors as potential biomarkers in experimental models of colon cancer 48
Immune Checkpoint Inhibitors and Myasthenic Syndromes: A Case Report of a Metastatic Renal Cell Carcinoma Patient Treated With Nivolumab 47
Clinical outcomes to pemetrexed-based versus non-pemetrexed-based platinum doublets in patients with KRAS-mutant advanced non-squamous non-small cell lung cancer 46
Osimertinib beyond disease progression in T790M EGFR-positive NSCLC patients: a multicenter study of clinicians’ attitudes 45
Topical menthol for treatment of chemotherapy-induced peripheral neuropathy 45
Haloperidol for the treatment of opioid addiction in advanced cancer patients: a case series 45
Family history of cancer as surrogate predictor for immunotherapy with anti-PD1/PD-L1 agents: Preliminary report of the FAMI-L1 study 44
Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study 44
Weekly alternate intensive regimen FIrB/FOx in metastatic colorectal cancer patients: An update from clinical practice 44
INfluenza Vaccine Indication during therapy with Immune checkpoint inhibitors: A transversal challenge. the INVIDIa study 43
The PERSONS score for symptoms assessment in simultaneous care setting: A pilot study 43
Impact of primary tumor location in patients with RAS wild-type metastatic colon cancer treated with first-line chemotherapy plus anti-EGFR or anti-VEGF monoclonal antibodies: A retrospective multicenter study 43
Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events 43
First-line carboplatin/nab-paclitaxel in advanced ovarian cancer patients, after hypersensitivity reaction to solvent-based taxanes: a single-institution experience 42
Weighing the role of skeletal muscle mass and muscle density in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: a multicenter real-life study 42
Evaluation of prognostic factors for survival in transverse colon cancer 42
The possible different roles of denosumab in prevention and cure breast cancer bone metastases: A ‘hypothesis-generator’ study from clinical practice 41
Single-institution study of correlations between skeletal muscle mass, its density, and clinical outcomes in non-small cell lung cancer patients treated with first-line chemotherapy 40
Predictive value of skeletal muscle mass for immunotherapy with nivolumab in non-small cell lung cancer patients: A “hypothesis-generator” preliminary report 40
Cancer care after natural disaster: Different countries, similar problems 40
Safe Administration of anti-PD-L1 Atezolizumab in a Patient with Metastatic Urothelial Cell Carcinoma and End-Stage Renal Disease on Dialysis 39
Evaluation of second-line anti-VEGF after first-line anti-EGFR based therapy in RAS wild-type metastatic colorectal cancer: The multicenter “SLAVE” study 39
Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50% 38
Family history of cancer and DNA damage response genes: Two sides of the same coin? 37
A reflection on the actual place of osimertinib in the treatment algorithm of EGFR-positive non-small cell lung cancer patients 37
A real-life multicenter study on body weight loss and body mass index in advanced Gastric Cancer patients treated with Ramucirumab-based second-line therapy 37
Timed-flat infusion (TFI) 5-fluorouracil with irinotecan and oxaliplatin in pancreatic adenocarcinomas: A single institution experience with FIr/FOx regimen 36
Weight loss and body mass index in advanced gastric cancer patients treated with second-line ramucirumab: a real-life multicentre study 35
Prognostic clinical factors in patients affected by non-small-cell lung cancer receiving Nivolumab 35
Clinical determinants of complete response to vismodegib in locally advanced basal cell carcinoma: a multicentre experience 35
Looking for a place for dose-dense TMZ regimens in GBM patients: An experience with MGMT exploratory evaluation 34
The treatment paradigm of right-sided metastatic colon cancer: harboring BRAF mutation makes the difference 32
Practical Advices About How To Handle Disease Progression During Osimertinib In EGFR-Mutant NSCLC Patients: Is It The Same Old Story? A Mini Review 31
Studio sul ruolo della storia familiare di neoplasie come fattore predittivo surrogato per l'immunoterapia con inibitori dei checkpoint immunitari PD-1/PD-L1 29
Anthracycline-Free Neoadjuvant Treatment in Patients with HER2-Positive Breast Cancer: Real-Life Use of Pertuzumab, Trastuzumab and Taxanes Association with an Exploratory Analysis of PIK3CA Mutational Status. 28
Impact of influenza syndrome and flu vaccine on survival of cancer patients during immunotherapy in the INVIDIa study 28
A multicenter study of skin toxicity management in patients with left-sided, RAS/BRAF wild-type metastatic colorectal cancer treated with first-line anti-EGFR-based doublet regimen: is there room for improvement? 28
Timed-flat infusion of 5-fluorouracil with docetaxel and oxaliplatin as first-line treatment of gastroesophageal adenocarcinoma: A single institution experience with the FD/FOx regimen 27
Rare bone toxicity associated with vismodegib 26
Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study 25
First-line chemotherapy with docetaxel, oxaliplatin, and timed-flat infusion 5Fluorouracil in metastatic gastro-esophageal adenocarcinomas: The experience with FD/FOx regimen 25
Knowledge and attitudes of Italian medical oncologists and palliative care physicians toward medical use of cannabis in cancer care: a national survey 24
"palliative" or "supportive": Is It Just a Matter of Word? 24
Retrospective evaluation of chemotherapy options in non-squamous non-small cell lung cancer (non-Sq NSCLC) patients (pts) unfit for standard platinum-based chemotherapy in clinical practice 22
Influenza vaccine indication during anticancer therapy with immune-checkpoint inhibitors: A transversal challenge for patient’s counselling – preliminary analysis of the INVIDIa study 22
Osimertinib as induction therapy for oligometastatic non-small cell lung cancer with EGFR mutation: a case report 22
Prognostic relevance of Hormonal Receptor positive Status in HER2-positive Metastatic Breast Cancer Patients: Retrospective Analysis in Real Life 21
Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma 17
Post-Induction Management in Patients With Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Treated With First-Line Anti-EGFR-Based Doublet Regimens: A Multicentre Study 5
The dynamics of circulating tumour DNA (ctDNA) during treatment reflects tumour response in advanced melanoma patients 5
Totale 2.455
Salva come PNG Salva come JPEG
Categoria #
all - tutte 10.939
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 10.939
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201915 0 0 0 0 0 0 0 0 0 0 1 14
2019/2020275 8 1 8 0 0 14 91 16 64 10 1 62
2020/2021423 13 58 2 58 55 8 58 9 75 6 60 21
2021/2022209 4 1 16 8 11 4 3 19 23 2 23 95
2022/20231.193 65 95 9 148 88 114 2 89 516 6 43 18
2023/2024274 38 7 17 20 29 110 3 49 0 1 0 0
Totale 2.455